New Nordic Healthbrands AB has decided to postpone the application for listing on Nasdaq Main Market Stockholm due to the Covid-19 pandemic. The new plan for listing is in 2022.

Following our announcement on February 28, 2020, we confirm that we are preparing for listing on Nasdaq Main Market Stockholm.

However, we have decided to postpone the application until the Covid-19 pandemic has eased.

We expect that the application will be made in 2021 in order to publish the prospectus after the publication of the annual report for 2021 and obtain listing latest by year-end 2022.

New Nordic is expanding internationally. A listing on the Nasdaq Main Market will attract more interest in the new Nordic share from international investors and institutional investors.

New Nordic does not currently plan to issue more shares in the company in combination with the listing.

Karl Kristian Bergman Jensen, CEO

New Nordic Healthbrands AB
Södra Förstadsgatan 3 C
SE-211 43 Malmö
Sweden

Malmö 26 March 2021

Contact:

Karl Kristian Bergman Jensen, CEO +46 40-239520 (switchboard),
Ivan Ruscic, CFO +46 40-239520 (switchboard),

This information is information that New Nordic Healthbrands AB (publ) is obliged to make public, pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 26 March 2021 at 8:00 CET.

New Nordic Healthbrands AB (publ), SE-211 43 Malmö,Sweden Phone +46-40-239520, email: [email protected]. Registered office: Malmö, Reg. No. 556698-0453.

Certified advisor: Mangold Fondkommission AB. +46 8 503 01 550.

New Nordic Healthbrands AB (publ) was founded in 1990 and is quoted on Nasdaq First North Growth Market Sweden since 2007. The company's business concept is to offer the most effective and safe food supplements, natural medicines and cosmetic products for specific health and beauty concerns. New Nordic's branded products are now available in 40 countries in pharmacies, beauty stores and health stores. The New Nordic Group has it's own small sales and marketing companies in most European Countries, Canada and the US, to organise local marketing campaigns, serve the pharmacy and health retailers and serve the end consumers. In 2020, sales were 450 MSEK. Nearly all New Nordic products sold worldwide are manufactured in Scandinavia. For further information, visit www.newnordic.com.

New Nordic Healthbrands AB (publ) Six Months Report January - June 2022

SIX MONTHS 2022

  • Net sales amounted to MSEK 254.0 (268.9), a decrease of 10.7 percent in local currencies and 5.5 percent in SEK.
  • Gross margin decreased to 66.0 percent (68,0).
  • EBITDA decreased to MSEK -4.3 (24.6).
  • Operating profit decreased to MSEK -4.9 (24.1).
  • Profit after tax for the period decreased to MSEK -6.5 (10.1).
  • Earnings per share after tax decreased to SEK -1.05 (3.08).  

Q2 2022

  • Net sales amounted to MSEK 130.7 (141.1), a decrease of 12.6 percent in local currencies and 7.4 percent in SEK.
  • Gross margin decreased to 64.8 percent (68.8).
  • EBITDA decreased to MSEK -6.3 (11.2).
  • Operating profit decreased to MSEK -6.6 (10.9).
  • Profit after tax for the period decreased to MSEK -7.5 (8.7).
  • Earnings per share after tax decreased to SEK -1.21 (1.41).  


New Nordic Healthbrands AB (publ) Three Month Report January - March 2022

Q1 2022

  • Net sales amounted to MSEK 123,3 (127,8), a decrease of 8,6 percent in local currencies and 3,5 percent in SEK.
  • Gross margin increased to 67,2 percent (67,0).
  • EBITDA decreased to MSEK 2,0 (13,4).
  • Operating profit decreased to MSEK 1,8 (13,2).
  • Profit after tax for the period decreased to MSEK 1,0 (10,4).
  • Earnings per share after tax decreased to SEK 0,16 (1,68).


Kallelse till årsstämma i New Nordic Healthbrands AB (publ)

Aktieägarna i New Nordic Healthbrands AB (publ) kallas härmed till årsstämma.


New Nordic Healthbrands AB (publ) Full Year Report January - December 2021

FULL YEAR 2021

  • Net sales amounted to MSEK 514,8 (450,1), an increase of 17,3 percent in local currencies and 14,4 percent in SEK.
  • Gross margin decreased to 68.0 percent (68,7).
  • EBITDA increased to MSEK 29.5 (24.6).
  • Operating profit increased to MSEK 28.5 (23.8).
  • Profit after tax for the period increased to MSEK 21.3 (17.8).
  • Earnings per share after tax increased to SEK 3.44 (2.87).

New Nordic Healthbrands AB (publ) has decided to postpone the application for listing on Nasdaq Main Market Stockholm

New Nordic Healthbrands AB (publ) has decided to postpone the application for listing on Nasdaq Main Market Stockholm. The application will be made late 2022 with the aim to list in 2023


New Nordic Healthbrands AB (publ) Nine Month Report January - September 2021

NINE MONTHS 2021

  • Net sales amounted to MSEK 393.8 (332.3), an increase of 22.9 percent in local currencies and 18.5 percent in SEK.
  • Gross margin decreased to 68.9 percent (69.3).
  • EBITDA increased to MSEK 33.5 (20.0).
  • Operating profit increased to MSEK 32.8 (19.4).
  • Profit after tax for the period increased to MSEK 25.8 (15.1).
  • Earnings per share after tax increased to SEK 4.16 (2.44).

New Nordic Healthbrands AB (publ) Six Month Report January - June 2021

FIRST HALF-YEAR 2021

  • Net sales amounted to MSEK 268.9 (217,0), an increase of 30.8 percent in local currencies and 23,9 percent in SEK.
  • Gross margin decreased to 68.0 percent (70.1).
  • EBITDA increased to MSEK 24.6 (11.8).
  • Operating profit increased to MSEK 24.1 (11.4).
  • Profit after tax for the period increased to MSEK 19.1 (8.7).
  • Earnings per share after tax increased to SEK 3.08 (1.40).


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted